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Abstract 
Influenza A virus of swine origin caused the first pandemic of the 21st century. In accordance with WHO 
recommendations, pandemic influenza vaccines were manufactured using the A/California/07/2009 (H1N1) strain 
and these vaccines were first evaluated in preclinical studies.  
 
We evaluated the immunogenicity of the A/California/07/2009 (H1N1) vaccine in both naïve and influenza-primed 
mice. Animals were intramuscularly-immunized on D0 and D21 with 0.3 or 3 μg of hemagglutinin administered with 
or without AF03 adjuvant. Immunogenicity of the various formulations was compared to that of other seasonal H1N1 
and H5N1 strains. Additionally, we investigated the impact of prior or concomitant immunization with seasonal 
trivalent inactivated influenza vaccine (TIV). The immune response was assessed by hemagglutination inhibition and 
microneutralization assays. 
 
In naïve mice, a single dose of unadjuvanted A/H1N1/California/07/2009 vaccine elicited HI titers > 40, and a second 
vaccine dose strongly increased these titers. In the presence of AF03, even a low vaccine dosage elicited high 
antibody titers (HI titers > 700). The antibody responses induced by both unadjuvanted and adjuvanted-vaccine were 
similar to those induced by other seasonal H1N1 strains and were superior to those induced by H5N1 vaccine strains. 
In mice previously primed with TIV, the unadjuvanted pandemic (H1N1) 2009 vaccine induced higher functional 
antibody titers than in naïve mice. However the AF03-adjuvanted vaccine induced similar antibody titers in both 
naïve and primed mice. The concomitant administration of TIV together with pandemic (H1N1) 2009 vaccine did not 
affect antibody responses generated against A/California/07/2009 or A/Brisbane/59/2007 seasonal H1N1 strain. 
 
The pandemic (H1N1) 2009 unadjuvanted influenza vaccine was shown to be immunogenic in mice after a single 
immunization. Formulation of the vaccine with AF03 adjuvant strongly increased its immunogenicity and enabled 
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antigen dose-sparing. No negative effect of prior or concomitant vaccination with seasonal TIV was observed on the 
immune response to the pandemic (H1N1) 2009 or to the H1N1 strain contained in the seasonal TIV. 
 
© 2011 Published by Elsevier Ltd. Selection and peer-review under responsibility of Prof. Ray Spier 
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1. Introduction  
Human infection with the pandemic influenza A (H1N1) 2009 virus was first identified in April 2009 
[1] and on June 11, 2009 the World Health Organization (WHO) declared a pandemic by raising the 
worldwide pandemic alert level to phase 6. This novel strain is antigenically and genetically distinct from 
other H1N1 influenza strains in circulation since 1977 [2].In accordance with WHO recommendations, 
pandemic influenza vaccines have been manufactured using the A/California/07/2009 (H1N1) strain.. In 
preparation for clinical studies, mouse studies were designed to assess the potential requirement for an 
adjuvant, antigen dose, and the immunization regimen. Immunogenicity of the various formulations was 
compared to that of other H1N1 seasonal strains and a H5N1 strain. Groups of naïve mice and mice 
primed against seasonal influenza strains were included to model the human population, which includes 
persons who have been primed to seasonal influenza through infection or vaccination as well as 
individuals with no prior exposure to influenza (usually young children). Moreover, the effect of 
concomitant immunization with seasonal trivalent inactivated influenza vaccine (TIV) given at the same 
or at a separate injection site on antibody responses against pandemic (H1N1) 2009 and H1N1 seasonal 
strains was evaluated. 
2. Material and Methods 
2.1. Experimental designs 
Naive or influenza-primed female BALB/c mice of 6-week old were immunized intramuscularly on D0 
and D21 with 0.3 μg or 3 μg of hemagglutinin (HA) from NYMC X-179A A/California/07/2009 (H1N1) 
or other A/H1N1 seasonal vaccines (A/Solomon Islands/03/2006, A/Brisbane/59/2007 and A/New 
Caledonia/20/1999) and A/H5N1 (A/Vietnam/1194/04/NIBRG-14) vaccine strain. All vaccines were 
produced using an egg-based manufacturing process. Hemagglutinin content of the vaccine was measured 
using the single radial immunodiffusion (SRID) assay. Each HA dose was formulated with or without the 
AF03 oil-in-water emulsion adjuvant (sanofi pasteur, Lyon, France). The Influenza priming was 
performed with two different trivalent inactivated vaccines (TIV, Vaxigrip, sanofi pasteur, Lyon, 
France) at 1/10 of the human dose (1.5 μg of HA per strains) 43 days before immunization with 
A/H1N1/California/07/2009 monovalent vaccine. The first seasonal vaccine formulation (TIV1) was 
prepared using the Northern hemisphere formation (2005–06) containing the strains A/New 
Caledonia/20/99 (H1N1), A/NewYork/55/2004 (H3N2) and B/Jiangsu/10/2003. The second seasonal 
vaccine formulation (TIV2) was prepared using the Northern hemisphere formulation (2009–10) 
containing A/Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) and B/Brisbane/60/2008. For 
concomitant administration, mice were vaccinated on D0 with 2.2 μg of HA of unadjuvanted or AF03-
adjuvanted A/H1N1/California/07/2009 monovalent vaccine and 1.5 μg of HA per strain of 2009–2010 
Northern Hemisphere (TIV2). Vaccinations were performed intramuscularly either at separate injection 
sites (50 μl H1N1 in the left hind leg, 50 μl TIV in the right hind leg) or at the same injection site as a mix 
(TIV and H1N1 extemporaneously mixed with 50 μl administered in each hind leg).  
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The study was approved by the local Animal Ethics Committees and was performed under conditions 
meeting EU standards for animal experimentation. 
2.2. Hemagglutination Inhibition (HI) and Microneutralization (MN) assays 
HI and MN antibody responses were assessed on individual serum samples collected post the first 
immunization (day 21) and post the second immunization (day 42). Sera were treated with receptor 
destroying enzyme (RDE) for HI assays. The HI assay followed a standard protocol using either chicken 
or horse erythrocytes for A/H1N1 or A/H5N1 strains, respectively. 
Virus neutralizing antibodies specific for each influenza virus were determined as described by Rowe 
et al.[3]. The presence of viral protein in MDCK cells was detected using an HRP-labeled anti-NP mouse 
monoclonal antibody. Titers were expressed as the reciprocal of the highest dilution showing no 
hemagglutination or no neutralization (1/dil). HI and MN antibody titrations showed comparable results.  
 
Statistical analysis was performed using a method of analysis of variance with Restricted Maximum 
Likelihood estimation with a two-sided risk of 5% for the main effects and 10% for interactions terms. 
Calculations were performed with the aid of SAS v9.1 software (SAS, Cary, NC). 
 
3. Results 
3.1. Immunogenicity of Pandemic (H1N1) 2009 vaccine in comparison with A/H1N1 seasonal vaccines 
and A/H5N1 strain 
Among naïve mice, titers against the pandemic (H1N1) 2009 strain 21 days after the first injection of 
non-adjuvanted vaccine with 0.3 μg or 3 μg HA were 1:37 and 1:211 respectively. A second injection of 
the same vaccine induced a marked increase in titers measured on Day 42, three weeks after the second 
injection, with 1:788 and 1:1749, respectively (Figure 1, left panel). These titers were similar 
(A/Brisbane/59/2007 and A/Solomon Islands/3/2006 A/H1N1 strains) or higher (A/New 
Caledonia/20/1999 strain) than those elicited after immunization with other seasonal A/H1N1 strains. As 
expected, the immunogenicity of A/H1N1 strains was superior to that of the A/H5N1 strain as no specific 
antibodies were detected after one dose of non-adjuvanted A/H5N1/Vietnam/1194/04 vaccine.  
 
Compared with the HI antibody responses seen in mice vaccinated without adjuvant, HI titers in 
animals vaccinated with AF03-adjuvanted vaccine were more than 10-fold higher (p< 0.0001) (Figure 1, 
right panel). Titers induced by the adjuvanted 0.3 μg vaccine were at least as high as those induced by the 
non-adjuvanted 3 μg vaccine, i.e., the AF03 adjuvant provided an antigen dose-sparing effect of at least 
10-fold. The AF03-adjuvanted A/H1N1/California/07/2009 vaccine induced similar or higher functional 
antibody responses than other AF03-adjuvanted A/H1N1 seasonal strains and higher antibody responses 
than the A/H5N1 pandemic strain, after a single and two immunization doses.  
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Figure 1: HI antibody responses (GMTs 95% CI) against each homologous vaccine strain measured in sera collected from naïve 
BALB/c mice after one or two immunizations with 0.3 or 3 μg of HA of either unadjuvanted or AF03-adjuvanted monovalent 
influenza vaccines 
 
 
 
 
Figure 2: HI Titers (GMTf 95% CI) elicited in naïve or seasonal TIV-primed BALB/c mice after one or two immunizations with 
0.3 or 3 μg HA of either unadjuvanted or AF03-adjuvanted pandemic influenza A (H1N1) 2009 vaccine 
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3.2. Effect of influenza immune status (prior immunization with TIV)  
Forty-three days after TIV priming, mean HI titers were 1:11 against the A/New Caledonia/20/99 
(H1N1) strain (TV1) and 1:260 against A/Brisbane/60/2008 (H1N1) strain (TV2) (data not shown). The 
two seasonal vaccine formulations provided groups of mice with either "low" (TV1 group) or "high" (TV2 
group) levels of seasonal H1N1 antibody responses. Seasonal TIV priming induced no detectable cross-
reactive antibody response against the pandemic (H1N1) 2009 strain (detection limit 1:10).  
 
As previously described, among naïve mice, HI titers  40 against the pandemic (H1N1) 2009 strain 
were measured 21 days after the first injection of non-adjuvanted vaccine with 0.3 μg or 3 μg HA and a 
second injection of the same vaccine induced a marked increase in titers (Figure 2, left panel). Noticeably, 
antibody titers in groups of mice that had been primed with TIV were 1.6-fold higher (TV1-primed mice) 
and up to 5-fold higher (TV2-primed mice) than those in the group of naïve mice (p < 0.01).  
 
Compared with the HI antibody responses seen in mice vaccinated without adjuvant, HI titers in 
animals vaccinated with AF03-adjuvanted vaccine were more than 10-fold higher in naïve mice and from 
3- to 10-fold higher in seasonal influenza-primed mice (p< 0.001).(Figure 2, right panel). In contrast to the 
results seen in groups immunized with a non-adjuvanted vaccine, TIV priming had no demonstrable effect 
on the immune responses generated against either adjuvanted vaccine. Thus, at each time-point no 
significant differences in HI titers were detected between the groups of unprimed and TIV-primed animals 
(p> 0.07).  
 
3.3. Effect of concomitant administration of seasonal TIV with the pandemic influenza A (H1N1) 2009 
vaccine
HI antibody response against the A/H1N1/California/07/2009 or A/H1N1/Brisbane/57/2009 vaccine 
strains was assessed in individual sera collected three weeks after the first vaccine administration at D21. 
HI results expressed as geometric means titers (GMT) and 95% confidence intervals are represented in 
Figure 3 and Figure 4, respectively 
 
The concomitant administration of TIV together with either the unadjuvanted or the AF03-adjuvanted A/H1N1 
vaccine did not affect antibody responses generated against A/California/07/2009 or A/Brisbane/59/2007 
seasonal H1N1 strain, when vaccines were administered concomitantly at two distinct sites. The AF03 
adjuvant strongly increased the immune response induced by TIV only when TIV and AF03-adjuvanted 
A/H1N1 vaccine were formulated and administered together and not when TIV and AF03-adjuvanted 
A/H1N1 vaccine were administered concomitantly at separate sites. 
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Figure 3: HI Titers (GMT± 95% CI) against A/H1N1/California/07/2009 measured at D21 in sera of naïve BALB/c mice 
immunized with 2.2 μg of either unadjuvanted or AF03-adjuvanted pandemic influenza A (H1N1) 2009 vaccine administered at D0 
concomitantly to 2009-2010 seasonal trivalent influenza vaccine 
 
Figure 4 : HI Titers (GMT± 95% CI) against A/H1N1/Brisbane/59/2007 measured at D21 in sera of naïve BALB/c mice immunized 
with 2.2 μg of either unadjuvanted or AF03-adjuvanted pandemic influenza A (H1N1) 2009 vaccine administered at D0 
concomitantly to 2009-2010 seasonal trivalent influenza vaccine 
4. Discussion 
These studies demonstrated that the pandemic (H1N1) 2009 unadjuvanted influenza vaccine was 
immunogenic in mice after a single immunization as well as that the AF03-formulation highly increases 
its immunogenicity and enables dose-sparing. This immunogenicity was similar or superior to that of 
other A/H1N1 seasonal vaccines and superior to that of A/H5N1 pandemic vaccine. HI titers obtained 
with AF03 adjuvant in mice are consistent with clinical studies of H5N1 influenza vaccines, in which HI 
responses were significantly increased by the addition of this emulsion-based adjuvant. Without adjuvant, 
H5N1 vaccines have been generally observed to be weakly immunogenic, even at HA doses of 30 μg HA 
or higher, whereas an AF03-adjuvanted H5N1 vaccine was demonstrated to elicit antibody responses to 
protective levels in humans at doses of as little as 1.9 μg of HA [4, 5].  
 
Our results in mice confirmed and extended results obtained in human subjects that a single injection 
of pandemic influenza A (H1N1) 2009 vaccine with or without adjuvant was sufficient to induce 
protective antibody levels in humans. Noticeably, the specific response to pandemic influenza A (H1N1) 
2009 non-adjuvanted vaccine was enhanced when mice were previously primed with seasonal TIV. The 
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geometric mean HI antibody titer against the pandemic (H1N1) 2009 influenza strain was higher than 40 
in all groups with the exception of the group of naïve mice immunized with 0.3 μg HA of non-adjuvanted 
vaccine. A HI titer of 40 or more is generally considered to be associated with protection in humans 
against seasonal influenza [6, 7]. These results were in agreement with data from clinical trials in adults, 
that are mostly considered as a non-naïve to influenza antigens due to prior infections or vaccinations, 
showing that a single dose of 15 μg HA of unadjuvanted vaccine is immunogenic with antibody titers of 
40 or more detected in 97% of subjects [8]. In contrast to observations with non-adjuvanted vaccine, 
seasonal influenza priming did not appear to influence the immunogenicity of the AF03-adjuvanted 
vaccines, probably due to the strong primary response induced by the adjuvanted vaccine in all groups of 
mice.  
 
Moreover, no negative effect of concomitant vaccination with seasonal TIV was observed on the 
immune response to the pandemic (H1N1) 2009 or to the H1N1 strain contained in the seasonal TIV, 
when vaccines are administered at two distinct sites as recommended for vaccination in humans. These 
results were also in agreement with human clinical data from a trial evaluating sequential as well as 
simultaneous administration of the 2009 H1N1 influenza vaccine and the seasonal influenza vaccine in 
healthy adults that indicate that co-administration of the two vaccines does not impair the immune 
response to either one (trial sponsored by the National Institute of Allergy and Infectious Diseases 
(NIAID)). 
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